Engineered CHO Cell Lines
Therapeutic Protein Manufacturing (Monoclonal Antibodies)
Commercial Feasibility TestingActive
Key Facts
Indication
Therapeutic Protein Manufacturing (Monoclonal Antibodies)
Phase
Commercial Feasibility Testing
Status
Active
Company
About CHO-plus
Founded in 2014, CHO Plus addresses capacity constraints and high costs in biopharmaceutical manufacturing through proprietary cell line engineering. The company's technology platform creates GMP-compliant CHO and HEK-293 cell lines with dramatically enhanced productivity for monoclonal antibodies and AAV vectors. CHO Plus operates as a technology licensor, planning to generate revenue through royalties from biopharma partners using their engineered cell lines in commercial manufacturing processes.
View full company profile